Patients who experience dermatologic toxic effects from epidermal growth factor receptor inhibitors (EGFRIs) have a high prevalence of skin and nail infections, according to a new study.
Patients who experience dermatologic toxic effects from epidermal growth factor receptor inhibitors (EGFRIs) have a high prevalence of skin and nail infections, according to a new study.